SB284 protects Kansas health providers participating in the federal 340B Drug Pricing Program from interference by drug manufacturers. It prohibits manufacturers from denying or restricting delivery of 340B drugs or requiring extra data beyond what federal or state law demands.

The Kansas State Senate passed SB284 on March 20, 2025 by a vote of 34 to 6. We have assigned pluses to the nays because states should not support any programs that lack authorization under Article I, Section 8, of the U.S. Constitution. By forcing private drug manufacturers to comply with mandates that interfere with their freedom to contract, protected under Article I, Section 10, this bill violates constitutional safeguards, undermines federalism, and erodes free-market principles. Rather than protecting liberty, SB284 entrenches an unconstitutional federal welfare program and expands government interference in healthcare.